Exploring the Glycosylation of Serum CA125

International Journal of Molecular Sciences

Radka Saldova¹  Weston B. Struwe¹  Kieran Wynne³  Giuliano Elia³  Michael J. Duffy² 

[1] NIBRT GlycoScience Group, National Institute for Bioprocessing Research and Training, Fosters Avenue, Mount Merrion, Blackrock, Dublin 4, Ireland; E-Mails:;UCD School of Medicine and Medical Science, Conway Institute of Biomolecular and Biomedical Research, University College Dublin, Dublin 4, Ireland; E-Mail:;The Mass Spectrometry Resource, Conway Institute, University College Dublin, Dublin 4, Ireland; E-Mails:

关键词: CA125;    N-glycosylation;    biomarker;    ovarian cancer;   

DOI  :  10.3390/ijms140815636

来源: mdpi

【 摘 要 】

Ovarian cancer is the most lethal gynaecologic cancer affecting women. The most widely used biomarker for ovarian cancer, CA125, lacks sensitivity and specificity. Here, we explored differences in glycosylation of CA125 between serum from patients with ovarian cancer and healthy controls. We found differences between CA125 N-glycans from patient sera compared to controls. These include increases in core-fucosylated bi-antennary monosialylated glycans, as well as decreases in mostly bisecting bi-antennary and non-fucosylated glycans in patients compared to controls. Measurement of the glycosylated state of CA125 may therefore provide a more specific biomarker for patients with ovarian cancer.

【 授权许可】

CC BY   
© 2013 by the authors; licensee MDPI, Basel, Switzerland